Guided Antitumoural Drugs : (Imidazol-2-ylidene)(L)gold(I) Complexes Seeking Cellular Targets Controlled by the Nature of Ligand L by Bär, Sofia I. et al.
& Ligand Effects
Guided Antitumoural Drugs: (Imidazol-2-ylidene)(L)gold(I)
Complexes Seeking Cellular Targets Controlled by the Nature of
Ligand L
Sofia I. Br+, Madeleine Gold+, Sebastian W. Schleser, Tobias Rehm, Alexander Br,
Leonhard Kçhler, Lucas R. Carnell, Bernhard Biersack, and Rainer Schobert*[a]
Abstract: Three [1,3-diethyl-4-(p-methoxyphenyl)-5-(3,4,5-
trimethoxyphenyl)imidazol-2-ylidene](L)gold(I) complexes,
4 a (L = Cl), 5 a (L = PPh3), and 6 a (L = same N-heterocyclic
carbene (NHC)), and their fluorescent [4-(anthracen-9-yl)-1,3-
diethyl-5-phenylimidazol-2-ylidene](L)gold(I) analogues, 4 b,
5 b, and 6 b, respectively, were studied for their localisation
and effects in cancer cells. Despite their identical NHC li-
gands, the last three accumulated in different compartments
of melanoma cells, namely, the nucleus (4 b), mitochondria
(5 b), or lysosomes (6 b). Ligand L was also more decisive for
the site of accumulation than the NHC ligand because the
couples 4 a/4 b, 5 a/5 b, and 6 a/6 b, carrying different NHC li-
gands, afforded similar results in cytotoxicity tests, and tests
on targets typically found at their sites of accumulation,
such as DNA in nuclei, reactive oxygen species and thiore-
doxin reductase in mitochondria, and lysosomal membranes.
Regardless of the site of accumulation, cancer cell apoptosis
was eventually induced. The concept of guiding a bioactive
complex fragment to a particular subcellular target by sec-
ondary ligand L could reduce unwanted side effects.
Introduction
Although N-heterocyclic carbene (NHC) complexes have been
much used as catalysts, their medicinal relevance was recog-
nised surprisingly late, given their chemical stability under
physiological conditions and their structural flexibility.[1, 2]
Unlike cisplatin (CDDP) and related platinum coordination
complexes, which all lead to DNA adducts, resulting in an in-
hibition of the cancer cell cycle and eventually in apoptotic
cancer cell death,[3] NHC complexes of various metals may ad-
dress a broader array of molecular targets. Complexes with the
character of delocalised lipophilic cations (DLCs) were found to
selectively accumulate in mitochondria, which can be ex-
plained by their negative inner transmembrane potential.[4, 5]
Because cancer cells have a more hyperpolarised mitochondrial
membrane potential (MMP) than normal cells, the selective ac-
cumulation of metal–carbene complexes with DLC character in
cancer cells can be expected.[5, 6] With the detection of antitu-
mour activity of the antirheumatic gold(I) compound aurano-
fin, (2,3,4,6-tetra-O-acetyl-1-thio-b-d-glucopyranosato)(triethyl-
phosphane)gold, gold complexes came to the fore as potential
anticancer drug candidates.[7] Auranofin mainly acts through
the inhibition of mitochondrial thioredoxin reductase (TrxR)
and by enhancing the mitochondrial permeability.[8, 9] Through
the inhibition of TrxR activity, the intracellular levels of reactive
oxygen species (ROS) rise, which damages predominantly
cancer cells because of their elevated ROS levels compared
with healthy cells.[10] As a result, cytochrome c is released into
the cytosol, triggering apoptotic cell death.[11] Due to their sta-
bility, NHC ligands can also be annulated and substituted in
multifarious ways, allowing the mimicking or combinatorial at-
tachment of pharmacophores to afford pleiotropic drugs.[12]
Herein, we report on NHC gold(I) complexes 4 a–6 a, carrying a
1,3-diethyl-4-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)imi-
dazol-2-ylidene ligand, akin to the natural antimitotic combre-
tastatin A4 (CA-4), and differing only in the second ligand on
the gold atom (Scheme 1). Preliminary studies had shown
strong cytotoxicity against cancer cells with IC50 values in the
low triple- to double-digit nanomolar range for complex 6 a,
but its actual mechanism of action remained unclear.[13] A
second series of complexes 4 b–6 b, bearing the same “second
ligands L”, yet a better detectable fluorescent 1,3-diethyl-4-(an-
thracen-9-yl)-5-phenylimidazol-2-ylidene ligand, were synthe-
sised and studied for their intracellular accumulation and their
modes of anticancer action. The aim of this study was to find
out whether ligand L could be used to set the site of accumu-
lation, and thus, the targets and nature of antitumour effects
of gold complexes with identical or closely related NHC li-
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gands. This was particularly tempting because similar cis-
[{bis(1,3-dibenzylimidazol-2-ylidene)Cl(L)}PtII] complexes were
previously shown by us to always accumulate in mitochondria,
regardless of the charge of the complex and nature of
ligands L.[14] Likewise, Ott et al. reported a triad of (1,3-
diethylbenzimidazol-2-ylidene)(L)gold(I) complexes with the
same ligands (L = Cl, PPh3, NHC), which all localised in the mi-
tochondria, albeit to different degrees.[15]
Results and Discussion
Synthesis
The new gold(I) NHC complexes were prepared from imidazoli-
um salts 3 a and 3 b (Scheme 1). Compound 3 b was synthe-
sised analogously to known compound 3 a by the van Leusen
reaction of toluenesulfonylmethyl isocyanide (TosMIC) reagent
1 with 9-formylanthracene, followed by N-alkylation and anion
exchange of the resulting imidazole 2. Reactions of 3 a and 3 b
with Ag2O and transmetalation of the corresponding silver car-
bene complexes with different amounts of [AuCl(SMe2)] afford-
ed mono- and bis-carbene gold(I) complexes 4 a/b and 6 a/b
analogously to literature procedures.[12, 13] New cationic com-
plex 5 a was prepared by the reaction of complex 4 a with tri-
phenylphosphane. Complex 5 b was obtained by diprotonation
of 3 b and reaction of the free carbene with [AuCl(PPh3)] . The
stability of all complexes 4–6 in aqueous solution was ascer-
tained by 1H NMR spectroscopic monitoring over a period of
72 h (see the Supporting Information).
Cytotoxicity against cancer cells
All complexes 4–6 had an antiproliferative effect, with IC50
values in the three-digit nanomolar to low double-digit micro-
molar range, on cells of the human cancer cell lines HCT-116wt,
its p53 knockout mutant HCT-116p53/ (both colon cancer),
518A2 (melanoma), HeLa, and multi-drug-resistant KB-V1Vbl
(both cervical carcinoma; Table 1). For complexes 4 a, 5 a and
6 a bearing a CA-4 analogous NHC ligand, we found that the
cytotoxicity increased with their DLC character, that is, in the
order 4 a<5 a<6 a, except for the KB-V1Vbl cells. A similar
trend was observed for the anthracenyl complexes (4 b<5 b<
6 b), with the exception of bis-NHC complex 6 b, which is less
active than phosphane complex 5 b in 518A2 melanoma and
HeLa cervical carcinoma cells. This conformity of cytotoxicities
of the a and b series of complexes suggests similar mecha-
nisms of action. Interestingly, all tested gold complexes, includ-
ing auranofin, were more active against the p53-knockout
mutant HCT-116p53/, if compared with its wild-type analogue
HCT-116wt expressing functional p53 protein. We assume that
complexes 4–6 induce cancer cell death in a way that is inde-
Scheme 1. Syntheses of complexes 4–6 : a) 9-formylanthracene, EtNH2/THF,
AcOH, EtOH, reflux, 2 h, then 1, K2CO3, reflux 6 h, 61 %; b) 1) EtI, MeCN,
reflux, 48 h; 2) NaBF4, acetone, RT, 1 h, 95 %; c) Ag2O (0.5 equiv), CH2Cl2, RT,
5 h, then [AuCl(SMe2)] (1 equiv), LiCl, RT, 24 h, 92 %; d) Ag2O (0.5 equiv),
CH2Cl2, RT, 5 h, then [AuCl(SMe2)] (0.5 equiv), RT, 24 h, 88 %; e) PPh3, NaBF4,
CH2Cl2, RT, 24 h, 79 %; f) [AuCl(PPh3)] , KOtBu, CH2Cl2, RT, 24 h, 70 %.
Table 1. Inhibitory concentrations, IC50
[a] [mm] , of complexes 4–6 upon application to cells of HCT-116wt and HCT-116p53/ knockout mutant colon carcino-
mas, 518A2 melanoma, HeLa and mdr KB-V1Vbl cervical carcinomas, and human adult dermal fibroblast cells HDFa.
IC50 [mm]
[a]
HCT-116wt HCT-116 p53/ 518A2 HeLa KB-V1Vbl HDFa
4 a 6.60.8 2.20.4 19.82.0 12.40.5 >50 24.63.4
4 b 16.40.2 8.40.3 7.90.8 23.71.1 5.91.3 9.01.3
5 a 1.10.3 0.60.1 5.00.3 3.60.7 0.60.2 5.80.9
5 b 1.30.6 0.40.1 2.90.5 1.80.4 2.20.2 5.90.2
6 a 0.20.02 0.050.001 0.40.1 0.30.02 4.60.2 1.40.2
6 b 0.30.03 0.20.05 5.50.4 3.60.4 0.70.2 3.20.4
auranofin 11.90.4 5.00.2 1.80.03 2.60.4 n.d.[b] 13.71.0
[a] Values are the means standard deviation (SD) determined in four independent experiments and derived from dose–response curves after 72 h incuba-
tion by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. [b] Not determined.
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pendent of p53, as already shown for auranofin[16, 17] and for re-
lated (1,3-diethylbenzimidazol-2-ylidene)gold(I) complexes.[18]
Complexes 4 b, 5 and 6 were also quite active against the
multi-drug-resistant cell line KB-V1Vbl, which expresses high
levels of Pg-p, an ATP-dependent efflux pump, capable of ex-
pelling a variety of xenobiotics. Complexes 5 a and 6 b appear
to have a particularly low affinity for Pg-p. Cationic complexes
5 b and 6 a showed some selectivity for cancer over non-malig-
nant cells and are particularly interesting candidates for further
studies.
Intracellular localisation
The fluorescent complexes 4 b, 5 b and 6 b were synthesised as
easy-to-track analogues of complexes 4 a, 5 a and 6 a, respec-
tively. Well-observable, flat 518A2 melanoma cells were treated
with the b complexes, then counterstained with dyes specifi-
cally accumulating in particular cancer-relevant cellular organ-
elles, and eventually fixed and examined through confocal mi-
croscopy (Figure 1). By counterstaining with Nuclear Green,
neutral chloride complex 4 b could be localised in the area of
the nucleus and to a minor degree in the cytoplasm. This is in
line with reports on the nuclear accumulation of neutral gold(I)
complexes bearing an aryl-substituted NHC ligand.[19, 20] Many
established first-line anticancer drugs target cancer cell
nuclei,[21] yet suffer from therapeutic shortcomings, including
off-target side effects and an early onset of resistance, owing
to insufficient nuclear accumulation.[22] Against this back-
ground, the enrichment of new (NHC)AuICl complex 4 b pre-
dominantly in cancer cell nuclei is remarkable. Cationic phos-
phane complex 5 b accumulated in the mitochondria, as dem-
onstrated by counterstaining of treated 518A2 cells with red
mitochondria-selective MitoTracker (Figure 1). Apparently, the
DLC character of this complex favours accumulation in the
negatively charged mitochondrial compartments over any po-
tential DNA intercalation of the planar anthracene residue. Mi-
tochondria are considered to be promising targets for cancer
therapy. A distinct disruption of the MMP typically results in
the induction of apoptosis. One of the pro-apoptotic stimuli is
an increased mitochondrial ROS production, which, in turn,
causes disruption of the MMP.[23] Cationic bis-NHC complex 6 b
accumulated mainly in lysosomes within the cytoplasm. It
Figure 1. Confocal fluorescence microscopy images of 518A2 melanoma cells incubated for 30 min with 30 mm of complexes 4 b–6 b (lex = 350 nm and
lem = 420–480 nm). The nuclei were counterstained with Nuclear Green LCS1 (abcam; lex = 514 nm and lem = 520–535 nm), the mitochondria with MitoTrack-
erTM (Thermo Fisher; lex = 580 nm and lem = 595–610 nm) and the lysosomes with acridine orange solution (5 mg mL
1, ABCR GmbH; lex = 350 nm and
lem = 600–660 nm). Images are representative of at least four independent experiments; 2000-fold magnification.
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should be noted that Gust et al. found an accumulation of all
three [1,3-diethyl-4,5-di(p-fluorophenyl)imidazol-2-ylidene](L)-
gold(I) analogues of complexes 4 a, 5 a and 6 a in the nuclei of
MCF-7 and HT-29 cells upon a 24 h long exposure.[24] So, the
organelle-selective accumulation of our a complexes after only
30 min might be a kinetic effect. The bottom row of Figure 1
shows confocal fluorescence microscopy images of 518A2 mel-
anoma cells treated with complex 6 b and lysotropic acridine
orange, as well as the good match of the blue fluorescence of
6 b (UV) with the orange fluorescence of the counterstained ly-
sosomes. Lysosomes are the recycling centres of the cell and
are involved in cellular digestion processes, such as autophagy,
endocytosis and phagocytosis. Moreover, the release of lysoso-
mal hydrolases, so called cathepsins, is involved in the induc-
tion of cell death.[25, 26] Cathepsins mediate caspase- and mito-
chondrion-independent cell death, especially in cancer cells
with mutations in genes involved in the classic apoptotic path-
way, for example, the TP53 tumour suppressor gene.[27]
Induction of cancer cell apoptosis
The majority of p53 mutations are missense mutations, as in
the case of 518A2 melanoma cells,[28] leading to the expression
of dysfunctional p53 proteins with oncogenic activities intensi-
fying malignant properties of cancer cells, such as clinical drug
resistance.[29] Because the p53-independent induction of cancer
cell apoptosis had been reported for auranofin[17, 30] and for
(1,3-diethylbenzimidazol-2-ylidene)gold(I) complexes,[18] we in-
vestigated if complexes 4–6 also lead to an activation of apop-
tosis (Figure 2). Upon treatment of 518A2 melanoma cells with
these complexes, the activation of effector caspases-3 and -7
was observed, which we assumed to be p53 independent,
given the results from our cytotoxicity studies. The treated
cells showed the typical morphological signs of apoptosis, as
well as translocalisation of phosphatidylserines to the outer
leaflet of the plasma membrane, which indicated early rather
than late apoptosis or necrosis (see the Supporting Informa-
tion). Because about 50 % of all human tumours bear p53 mu-
tations, drugs that induce p53-independent programmed cell
death are of particular interest.[31, 32]
Mechanism of action of complexes 4 a and 4 b in the
nucleus
The antiproliferative effect of CDDP and other platinum com-
plexes is based mainly on their interaction with cellular
DNA.[3b, 33] Because of the localisation of neutral complex 4 b in
the nuclear area, a potential DNA interaction of 4 b and its
close structural analogue 4 a was examined by ethidium bro-
mide (EtdBr) saturation assays (Figure 3) and electrophoretic
mobility shift assays (EMSAs; Figure 4).
Addition of complexes 4 a or 4 b to linear, double-stranded
salmon sperm DNA led to a distinct concentration-dependent
displacement, and thus, to a reduction of the fluorescence of
intercalated EtdBr, exceeding that caused by CDDP by far. This
suggests a strong interaction of both complexes 4 with this
DNA form, possibly associated with an alteration of the DNA
morphology. Auranofin showed no such effect (Figure 3). In
the EMSA with circular plasmid DNA, a slight relaxation, that is,
despiralisation, of the covalently closed circular (ccc) DNA form
for the benefit of the open circular (oc) form was observed
after incubation with complex 4 a, and a stronger relaxation
after treatment with complex 4 b (Figure 4). In contrast to
CDDP, gold NHC complexes are known to bind non-covalently
to DNA, which may be the reason for their weaker effects in
the EMSA.[34]
Although auranofin had previously been reported to interact
neither with linear DNA nor with circular plasmid DNA,[35] vari-
ous other gold(I) complexes with readily displaceable ligands
(e.g. , Cl) had shown affinity to different types of DNA.[35, 36] Ir-
reparable DNA damage induces apoptosis, normally triggered
by the tumour suppressor protein p53. However, apoptosis as
a consequence of DNA damage caused by metal complexes
had also been reported to proceed independently of p53,[37, 38]
through the mitogen-activated protein kinase (MAPK) signal-
Figure 2. Induction of effector caspase-3/-7 activity in 518A2 melanoma cells
after treatment with 5 mm 4–6 for 6 h, measured by means of the Apo-ONE
Homogenous Caspase-3/7 Assay Kit (Promega). CDDP was used as a positive
control. The vitality of cells was simultaneously tested by MTT assays and
was >80 % for all experiments, except for complex 6 a (70 %). All experi-
ments were performed in triplicate and results quoted as meansSD. The
solvent-treated negative control was set to 100 %.
Figure 3. EtdBr saturation assays with 25, 50, 75 and 100 mm 4 a, 4 b and aur-
anofin. CDDP was used as a positive control. Negative controls were treated
with an equivalent amount of solvent (DMF or H2O). All experiments were
carried out in triplicate with negative controls set to 100 %.
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ling pathway involving JNK, p38 and ERK1/2.[37, 18] Whether
complexes 4, which we have found to induce cancer cell apop-
tosis and to be cytotoxic independently of functional p53, op-
erate by a similar mechanism remains to be shown. At present,
we cannot exclude that their reactions with further biologically
relevant macromolecules might also play a role.[39]
Mechanism of action of complexes 5 a and 5 b in mito-
chondria
Because cationic triphenylphosphane complex 5 b was local-
ised in the mitochondria of 518A2 melanoma cells, we antici-
pated a mitochondria-associated mode of action for 5 b and
closely related complex 5 a. The anticancer effect of auranofin,
and several other gold(I) complexes, mainly relies on the inhib-
ition of TrxR.[40, 41] TrxRs, which catalyse the reduced nicotina-
mide adenine dinucleotide phosphate (NADPH)-dependent re-
duction of the redox protein thioredoxin (Trx) and other com-
pounds, are key enzymes for cellular protection against oxida-
tive stress.[42] To date, three different isoforms of TrxR are
known: cytosolic TrxR1, mitochondrial TrxR2 and testis-specific
TrxR3.[43] Gold complexes, such as auranofin, are thought to in-
hibit TrxRs by releasing monovalent AuI species, which bind to
selenocysteine residues in the active site of the enzyme.[44] This
is in line with reports that mono-NHC gold(I) complexes with
good leaving groups, such as halides or phosphanes, are
better TrxR inhibitors than bis-NHC complexes.[45] For instance,
sub-micromolar IC50 values were reported by Gust et al.
for donor-substituted (1,3-diethyl-4,5-diarylimidazol-2-ylide-
ne)(PPh3)gold(I) complexes,
[24] and by Ott et al. for benzimid-
azol-2-ylidene analogues,[15, 46] whereas few inhibitory bis(1,3-di-
arylimidazol-2-ylidene) complexes have been reported, to
date.[45, 47]
If applied in low sub-micromolar concentrations, complexes
5 a and 5 b strongly inhibited the panTrxR activity in colorimet-
ric TrxR microplate assays with 5,5’-dithiobis(2-dinitrobenzoic
acid (DTNB; Ellman’s reagent) as a substrate (Figure 5). Because
many tumours have elevated TrxR levels,[43] and tumour cells
are more sensitive to oxidative stress, due to their a priori high
intracellular ROS levels relative to non-malignant cells, TrxR are
interesting targets for selective antitumour therapy.
TrxR inhibition generally leads to an accumulation of oxi-
dised Trx and ROS in mitochondria, resulting in an increase of
mitochondrial permeability.[40] Upon treatment of 518A2 mela-
noma cells with complexes 5 a and 5 b, we observed a distinct
reduction of the MMP through a fluorescence-based micro-
plate assay (Figure 6), exceeding that induced by auranofin,
which is in keeping with their stronger TrxR inhibition.
We confirmed these results by an assessment of the intracel-
lular ROS concentrations after treatment of 518A2 melanoma
cells with auranofin, CCCP and complexes 5 a and 5 b using
the cell permeant, fluorogenic dye 2’,7’-dichlorofluorescein di-
acetate (DCFH-DA). After diffusion into the cells, DCFH-DA is
deacetylated by cellular esterases to a non-fluorescent com-
pound, which is later oxidised by hydroxyl, peroxyl or other
ROS to the intensely fluorescent 2’,7’-dichlorofluorescein (DCF),
detectable by fluorescence spectroscopy (Figure 7).
We conclude that the cytotoxicity of complexes 5 originates
mainly from their inhibition of TrxR in the mitochondria of
cancer cells and the subsequent alteration of the intracellular
ROS equilibrium.[40] Elevated concentrations of hydrogen per-
oxide and oxidised Trx2 affect further intra-mitochondrial tar-
gets, leading to the opening of the mitochondrial permeability
Figure 4. EMSAs with circular pBR322 plasmid DNA after 24 h treatment
with complexes 4 a or 4 b, as visualised by UV radiation. CDDP was used as a
positive control. Images are representative of at least two independent ex-
periments.
Figure 5. Concentration-dependent inhibition of TrxR activity in cell lysates
of 518A2 melanoma cells by gold(I) complexes 5 a and 5 b, and auranofin as
a positive control. TrxR-independent substrate reduction was accounted for
by experiments in the presence and absence of the specific TrxR inhibitor
aurothiomalate. All values are meansSD of at least three independent ex-
periments with negative controls set to 100 %.
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transition pore and/or to an increase of the permeability of the
outer membrane.[9, 48] As a result, hydrogen peroxide is released
into the cytosol where it oxidises cytosolic Trx1 irreversibly,
due to the inhibition of TrxRs. The elevated levels of hydrogen
peroxide and oxidised Trx in the cytosol then activate various
signalling pathways, eventually leading to apoptosis, which is
likely to be dependent on p38/ERK1/2, rather than p53, as
shown for auranofin.[40, 49] Because cancer cells, unlike non-ma-
lignant cells, are not normally susceptible to mitochondrial
membrane permeability transition, the induction of this condi-
tion by mitochondria-targeting complexes, such as 5, could be
exploited in a therapeutic context.[50]
Mechanism of action of complexes 6 a and 6 b in lysosomes
The cationic bis-NHC complex 6 b was localised in the lyso-
somes of 518A2 melanoma cells. Lysosomes mediate the deg-
radation of macromolecules of intracellular origin or those that
are internalised by endocytosis or phagocytosis.[51] These
single-membrane acidic organelles (pH 4.5–4.8) are involved in
various cellular pathways and different types of cell death, and
their functionality is thus inevitable for cellular homeostasis.[51]
Various forms of cellular stress lead to lysosomal swelling and
lysosomal membrane permeabilisation (LMP), resulting in the
release of intralysosomal cargo into the cytoplasm.[51] Amongst
others, cathepsins B and D are released into the cytoplasm
under stress, where they induce different forms of cell death,
including the p53-independent, lysosome-dependent apoptot-
ic cell death.[26, 31, 51, 52] To detect a potential induction of LMP by
complexes 6, we performed a time-dependent staining of lyso-
somes in solvent- and complex-treated 518A2 melanoma cells
(Figure 8). Because the cytotoxicity of both complexes against
518A2 cells in MTT assays was quite different (IC50(6 a) = 0.4 mm,
IC50(6 b) = 5.5 mm), we adjusted their concentrations according-
ly to ensure a sufficient cell viability. The incubation with either
complex 6 a or 6 b led to an induction of LMP. The lysotropic
orange dye used in this assay selectively accumulates in intact
acidic lysosomes. If LMP occurs, the dye is released into the cy-
tosol and the fluorescence of defined lysosomal compartments
disappears. As expected, complex 6 a, which had proved to be
more active in MTT assays, also led to faster lysosomal disrup-
tion after only 2 h of incubation. Cells treated with 6 b showed
first signs of LMP only after 4 h of treatment.
Conclusion
The [4-(anthracen-9-yl)-1,3-diethyl-5-phenylimidazol-2-ylidene]
(L)gold(I) complexes 4 b, 5 b, and 6 b accumulated quickly in
different compartments of 518A2 melanoma cells, that is, neu-
tral chlorido complex 4 b in the nuclei, cationic phosphane
complex 5 b in mitochondria and large delocalised cationic bis-
NHC complex 6 b in the lysosomes. The analogous a series of
complexes carried a slightly different 4,5-diarylimidazol-2-yl-
idene ligand. The fact that all couples 4 a/4 b, 5 a/5 b and 6 a/
6 b afforded similar results in cytotoxicity tests with cancer
cells, and in tests on targets typically found at the identified
sites of accumulation, supports the assumption that a com-
plexes localise similarly to the b complexes, and that the
nature of ligand L, which is responsible for the charge, size
and lipophilicity of the complex, is decisive for the site of accu-
mulation. However, this phenomenon might be limited to diva-
lent gold(I)–NHC or even to (imidazol-2-ylidene)gold(I) com-
plexes because a comparable series of cis-[bis(1,3-dibenzylimid-
azol-2-ylidene)]Cl(L)PtII[14] and (1,3-diethylbenzimidazol-2-ylid-
ene)(L)gold(I) complexes,[15] carrying the same ligands L (Cl,
PPh3 or the same NHC ligand), were previously shown to accu-
mulate in mitochondria, regardless of the charge of the com-
plex and the nature of ligand L. The different distributions of
DLC complexes 5 (in mitochondria) and 6 (in lysosomes) is ex-
plicable by the higher molecular weight and steric demand of
Figure 6. Relative MMP in 518A2 melanoma cells after treatment (45 min)
with complexes 5 a and 5 b (10 mm each). Carbonylcyanide-m-chlorophenyl-
hydrazone (CCCP) and auranofin (10 mm, each) were used as positive con-
trols and solvent-treated negative controls were set to 100 %. Assays were
carried out in triplicate.
Figure 7. Influence of gold(I) complexes 5 a and 5 b, and auranofin (10 mm
each), as well as CCCP (10 mm) as a positive control, on the levels of ROS in
518A2 melanoma cells, as determined by fluorescence-based DCFH-DA
assays after an incubation time of 1 h. Negative controls were treated identi-
cally with solvent. All values are mean valuesSD from at least four inde-
pendent experiments with negative controls set to 100 %.
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the latter, which are too large for embedding in the mitochon-
drial membrane, and thus, are dealt with by the cellular
“waste-to-energy plants”, the lysosomes. Once fully under-
stood, the concept of controlling the intracellular distribution
of metallodrugs by the choice of secondary ligands and charge
of the complex could be exploited in rational drug design.
For the mode of action of new complexes 4–6, we found an
eventual induction of p53-independent apoptotic cell death,
which was initiated by different effects of the three complex
types at their respective sites of accumulation.
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Complexes Seeking Cellular Targets
Controlled by the Nature of Ligand L
Striking gold : Through the choice of
their secondary ligand L, a series of [4,5-
diarylimidazol-2-ylidene](L)gold(I) com-
plexes targeted different cancer cell or-
ganelles (nuclei, mitochondria or lyso-
somes) where they interfered beneficial-
ly with molecular targets, such as DNA,
thioredoxin reductase, or lysosomal
membranes, to elicit p53-independent
apoptosis. Such guided metallodrugs
will help to minimise unwanted side ef-
fects by addressing limited arrays of tar-
gets.
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